Updates in Upper GI Cancers From ASCO and ASCO GI 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on updates in gastrointestinal cancers from the 2024 ASCO Annual Meeting and Gastrointestinal Cancers Symposium.

EP. 1: Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

EP. 2: 4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

EP. 3: A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

EP. 4: Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

EP. 5: Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

EP. 6: Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.